MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Aβ

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 1, 2010, Pages 56-68

  Westmark, Cara J ^a   Westmark, Pamela R ^a   Malter, James S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

amyloid; APP; FMRP; FRAXAD; PTZ; Seizure; Tg2576

Indexed keywords

6 METHYL 2 (PHENYLETHYNYL)PYRIDINE; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; AMYLOID PRECURSOR PROTEIN; ANXIOLYTIC AGENT; CELL SURFACE RECEPTOR; FMR1 PROTEIN, MOUSE; FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA; PROTEASE NEXINS; PYRIDINE DERIVATIVE;

AGE; ANIMAL; ARTICLE; C57BL MOUSE; DISEASE MODEL; FRAGILE X SYNDROME; GENE EXPRESSION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; SEIZURE;

AGE FACTORS; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-ANXIETY AGENTS; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENE EXPRESSION; GENE SILENCING; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRIDINES; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SEIZURES;

EID: 77449134798     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007; 5: e52.
2. Hagerman RJ, Hagerman PJ. Physical and Behavioral Phenotype. Baltimore: John Hopkins University Press; 2002.
3. Velez L, Selwa LM. Seizure disorders in the el derly. Am Fam Physician. 2003; 67: 325-332.
4. Risse SC, Lampe TH, Bird TD, Nochlin D, Sumi SM, Keenan T, Cubberley L, Peskind E, Raskind MA. Myoclonus, seizures, and paratonia in alzheimer disease. Alzheimer Dis Assoc Disord. 1990; 4: 217-225.
5. Menendez M. Down syndrome, alzheimer's disease and seizures. Brain Dev. 2005; 27: 246-252.
6. Fmr1 knockout mice: A model to study fragile X mental retardation. the dutch-belgian fragile X consortium. Cell. 1994; 78: 23-33.
7. Chen L, Toth M. Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience. 2001; 103: 1043-1050.
8. Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, Ferri R, Oostra BA. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia. 2000; 41: 19-23.
9. Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, Bauchwitz RP. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav. 2004; 3: 337-359.
10. Westmark CJ, Westmark PR, Beard AM, Hildebrandt SM, Malter JS. Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. Int J Clin Exp Pathol. 2008; 1: 157-168.
11. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005; 49: 1053-1066.
12. Costantini C, Weindruch R, Della Valle G, Puglielli L. A TrkA-to-p75NTR molecular switch activates amyloid beta-peptide generation during aging. Biochem J. 2005; 391: 59-67.
13. Singh K, Gaur P, Prasad S. Fragile x mental retardation (fmr-1) gene expression is down regulated in brain of mice during aging. Mol Biol Rep. 2006.
14. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004; 27: 370-377.
15. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velicelebi G, Kuhn R. 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 1999; 38: 1493-1503.
16. Varney MA, Cosford ND, Jachec C, Rao SP, Sacaan A, Lin FF, Bleicher L, Santori EM, Flor PJ, Allgeier H, Gasparini F, Kuhn R, Hess SD, Velicelebi G, Johnson EC. SIB-1757 and SIB-1893: Selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther. 1999; 290: 170-181.
17. Huang RQ, Bell-Horner CL, Dibas MI, Covey DF, Drewe JA, Dillon GH. Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: Mechanism and site of action. J Pharmacol Exp Ther. 2001; 298: 986-995.
18. Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett. 2004; 367: 164-167.
19. Khandjian EW, Fortin A, Thibodeau A, Tremblay S, Cote F, Devys D, Mandel JL, Rousseau F. A heterogeneous set of FMR1 proteins is widely distributed in mouse tissues and is modulated in cell culture. Hum Mol Genet. 1995; 4: 783-789.
20. Lu R, Wang H, Liang Z, Ku L, O'Donnell W T, Li W, Warren ST, Feng Y. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci USA. 2004; 101: 15201-15206.
21. Hung AY, Koo EH, Haass C, Selkoe DJ. Increased expression of beta-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage. Proc Natl Acad Sci U S A. 1992; 89: 9439-9443.
22. Loffler J, Huber G. Beta-amyloid precursor protein isoforms in various rat brain regions and during brain development. J Neurochem. 1992; 59: 1316-1324.
23. Masliah E, Mallory M, Ge N, Saitoh T. Amyloid precursor protein is localized in growing neurites of neonatal rat brain. Brain Res. 1992; 593: 323-328.
24. Moya KL, Benowitz LI, Schneider GE, Allinquant B. The amyloid precursor protein is developmentally regulated and correlated with synaptogenesis. Dev Biol. 1994; 161: 597-603.
25. Torroja L, Packard M, Gorczyca M, White K, Budnik V. The drosophila beta-amyloid precursor protein homolog promotes synapse differentiation at the neuromuscular junction. J Neurosci. 1999; 19: 7793-7803.
26. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR. Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res. 1994; 666: 151-167.
27. Herard AS, Besret L, Dubois A, Dauguet J, Delzescaux T, Hantraye P, Bonvento G, Moya KL. siRNA targeted against amyloid precursor protein impairs synaptic activity in vivo. Neurobiol Aging. 2005.
28. Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, Zheng H. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. J Neurosci. 2005; 25: 1219-1225.
29. Mileusnic R, Lancashire CL, Rose SP. Amyloid precursor protein: From synaptic plasticity to alzheimer's disease. Ann N Y Acad Sci. 2005; 1048: 149-165.
30. Doyle E, Bruce MT, Breen KC, Smith DC, Anderton B, Regan CM. Intraventricular infusions of antibodies to amyloid-beta-protein precursor impair the acquisition of a passive avoidance response in the rat. Neurosci Lett. 1990; 115: 97-102.
31. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science. 1996; 274: 99-102.
32. An JJ, Gharami K, Liao GY, Woo NH, Lau AG, Vanevski F, Torre ER, Jones KR, Feng Y, Lu B, Xu B. Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell. 2008; 134: 175-187.
33. Blichenberg A, Rehbein M, Muller R, Garner CC, Richter D, Kindler S. Identification of a cis-acting dendritic targeting element in the mRNA encoding the alpha subunit of Ca2+/calmodulin-dependent protein kinase II. Eur J Neurosci. 2001; 13: 1881-1888.
34. Blichenberg A, Schwanke B, Rehbein M, Garner CC, Richter D, Kindler S. Identification of a cis-acting dendritic targeting element in MAP2 mRNAs. J Neurosci. 1999; 19: 8818-8829.
35. Kobayashi H, Yamamoto S, Maruo T, Murakami F. Identification of a cis-acting element required for dendritic targeting of activity-regulated cytoskeleton-associated protein mRNA. Eur J Neurosci. 2005; 22: 2977-2984.
36. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 2008; 31: 127-132.
37. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, McDonald TV, Jongens TA. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a drosophila model of fragile X syndrome. Neuron. 2005; 45: 753-764.
38. Chapman AG, Nanan K, Williams M, Meldrum BS. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology. 2000; 39: 1567-1574.
39. Lee AC, Wong RK, Chuang SC, Shin HS, Bianchi R. Role of synaptic metabotropic glutamate receptors in epileptiform discharges in hippocampal slices. J Neurophysiol. 2002; 88: 1625-1633.
40. Merlin LR. Differential roles for mGluR1 and mGluR5 in the persistent prolongation of epileptiform bursts. J Neurophysiol. 2002; 87: 621-625.
41. Jesse CR, Savegnago L, Rocha JB, Nogueira CW. Neuroprotective effect caused by MPEP, an antagonist of metabotropic glutamate receptor mGluR5, on seizures induced by pilocarpine in 21-day-old rats. Brain Res. 2008; 1198: 197-203.
42. Nagaraja RY, Grecksch G, Reymann KG, Schroeder H, Becker A. Group I metabotropic glutamate receptors interfere in different ways with pentylenetetrazole seizures, kindling, and kindling-related learning deficits. Naunyn Schmiedebergs Arch Pharmacol. 2004; 370: 26-34.
43. Zaidi SH, Malter JS. Amyloid precursor protein mRNA stability is controlled by a 29-base element in the 3'-untranslated region. J Biol Chem. 1994; 269: 24007-24013.
44. Zaidi SH, Malter JS. Nucleolin and heterogeneous nuclear ribonucleoprotein C proteins specifically interact with the 3'-untranslated region of amyloid protein precursor mRNA. J Biol Chem. 1995; 270: 17292-17298.
45. Westmark PR, Shin HC, Westmark CJ, Soltaninassab SR, Reinke EK, Malter JS. Decoy mRNAs reduce beta-amyloid precursor protein mRNA in neuronal cells. Neurobiol Aging. 2006; 27: 787-796.
46. Ceman S, Brown V, Warren ST. Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol Cell Biol. 1999; 19: 7925-7932.
47. Ceman S, Nelson R, Warren ST. Identification of mouse YB1/p50 as a component of the FMRP-associated mRNP particle. Biochem Biophys Res Commun. 2000; 279: 904-908.